CEDAR KNOLLS, N.J., April 29, 2010 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that interim data from an ongoing study demonstrated that its high-dose oral Eligen® B12 (1000mcg) given to individuals with low B12 levels restores normal B12 serum concentrations. Normal levels of serum B12 were achieved by all study participants who had taken Eligen® B12 (1000mcg) 15 days into the 90-day study when the first blood samples were taken. Normalization was maintained at all intervals up to and including Day 91. These data, in Abstract Number 8370, were presented on April 28, 2010 at the Experimental Biology 2010 Conference in Anaheim, California, by Dr. Cristina Castelli, Director of Clinical Development at Emisphere Technologies.
